John M Goldman

发表

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

Francisco Cervantes, Klaus Lechner, Thomas Fischer, 2003, The New England journal of medicine.

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias.

Sante Tura, Thomas Fischer, Alois Gratwohl, 2002, Blood.

Chronic myeloid leukemia: current status and controversies.

J. Goldman, John M Goldman, T. Mughal, 2004, Oncology.

Association between BMI-1 expression, acute graft-versus-host disease, and outcome following allogeneic stem cell transplantation from HLA-identical siblings in chronic myeloid leukemia.

J. Melo, M. Mohty, J. Goldman, 2008, Blood.

Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase.

Katayoun Rezvani, Holger W Auner, K. Rezvani, 2010, Blood.

Cord blood stem cells for hematopoietic stem cell transplantation in the UK: how big should the bank be?

Sergio Querol, G. Mufti, A. Little, 2009, Haematologica.

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

Francisco Cervantes, Simona Soverini, Giovanni Martinelli, 2013, Blood.

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.

Susan Branford, Andreas Hochhaus, Jaspal Kaeda, 2003, The New England journal of medicine.

Chronic myeloid leukemia-still a few questions.

J. Goldman, John M Goldman, 2004, Experimental hematology.

Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML.

J. Melo, J. Goldman, J. Apperley, 2006, Blood.

Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA.

Paul Metcalfe, Helen E White, Susan Branford, 2010, Blood.

Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

Katayoun Rezvani, Letizia Foroni, K. Rezvani, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.

Simona Soverini, Giovanni Martinelli, Susan Branford, 2006, Blood.

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

Francisco Cervantes, Thomas Fischer, Alois Gratwohl, 2006, The New England journal of medicine.

Chronic myeloid leukemia: a historical perspective.

J. Goldman, John M Goldman, 2010, Seminars in hematology.